Goldman Sachs
SLS icon

Goldman Sachs’s SELLAS Life Sciences SLS Stock Holding History

Goldman Sachs’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.64M Buy
585,035
+29,122
+5% +$201K ﹤0.01% 3378
2026
Q1 		$2.35M Buy
555,913
+144,259
+35% +$645K ﹤0.01% 4395
2025
Q4 		$1.55M Buy
411,654
+392,389
+2,037% +$763K ﹤0.01% 4804
2025
Q3 		$31K Sell
19,265
-446,241
-96% -$795K ﹤0.01% 6216
2025
Q2 		$1.02M Buy
+465,506
New +$714K ﹤0.01% 4687
2025
Q1 		– Sell
-15,683
Closed -$16.3K – 6372
2024
Q4 		$16.3K Buy
+15,683
New +$17.9K ﹤0.01% 5917
2018
Q1 		– Sell
-74
Closed -$29K – 6354
2017
Q4 		$29K Sell
74
-3
-4% -$1.45K ﹤0.01% 6057
2017
Q3 		$41K Sell
77
-11
-13% -$7.26K ﹤0.01% 6299
2017
Q2 		$76K Sell
88
-55
-38% -$47.8K ﹤0.01% 6228
2017
Q1 		$131K Buy
143
+137
+2,283% +$227K ﹤0.01% 5949
2016
Q4 		$18K Buy
+6
New +$34.9K ﹤0.01% 6671

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Goldman Sachs's SLS Position: Q2 2026 in Review

Goldman Sachs increased its SELLAS Life Sciences (SLS) stake by 5.2% in Q2 2026, buying an estimated $201K and bringing the position to 585,035 shares worth $8.64M. The position accounts for ﹤0.01% of the portfolio, ranked #3378.

Goldman Sachs first reported a position in SLS in Q4 2016 and has held it in 11 quarters since. 192 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • Goldman Sachs held 585,035 shares of SELLAS Life Sciences worth $8.64M as of Q2 2026.
  • Goldman Sachs bought 29,122 SELLAS Life Sciences shares in Q2 2026, an estimated $201K.
  • SELLAS Life Sciences made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3378 holding.
  • Goldman Sachs first reported a position in SELLAS Life Sciences in Q4 2016 and has held it in 11 quarters since.
  • 192 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.